CTSO
Cytosorbents Corporation
CTSO lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
CTSO Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Weak | |
| Unavailable |
CTSO's revenue is currently stable, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
CTSO PE Valuation
CTSO has no meaningful PE right now: it lost money over the past year.
CTSO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect CTSO's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
CTSO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$5.80 | -$2.40 |
| Q1 2026 | -$3.80 | +$1.80 |
| Q4 2025 | -$2.60 | +$5.00 |
| Q3 2025 | -$3.60 | +$3.60 |
| Q2 2025 | -$3.40 | +$7.20 |
| Q1 2025 | -$5.60 | +$6.20 |
| Q4 2024 | -$7.60 | +$5.20 |
| Q3 2024 | -$7.20 | +$3.60 |
CTSO is still losing money, but far less than before: $5.80 per share over the past year, against $18.40 at its worst in late 2022.
CTSO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $9.6M | +0.2% |
| Q1 2026 | $8.9M | +1.6% |
| Q4 2025 | $9.2M | +42% |
| Q3 2025 | $9.5M | +1% |
| Q2 2025 | $9.6M | -2.8% |
| Q1 2025 | $8.7M | -11% |
| Q4 2024 | $6.5M | -25% |
| Q3 2024 | $9.4M | +6.6% |
CTSO's revenue has grown year over year for four quarters in a row: $10M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -27% | +10 points |
| Q1 2026 | -34% | +10 points |
| Q4 2025 | -47% | +15 points |
| Q3 2025 | -30% | +17 points |
| Q2 2025 | -38% | -3 points |
| Q1 2025 | -45% | +5.8 points |
| Q4 2024 | -62% | +47 points |
| Q3 2024 | -47% | +37 points |
CTSO's operating margin was −27% last quarter, up 10 points from the same quarter a year ago.
CTSO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$597K | +$949.9K |
| Q1 2026 | -$1.2M | +$2.3M |
| Q3 2025 | -$2.6M | -$132.8K |
| Q2 2025 | -$1.5M | +$3.2M |
| Q1 2025 | -$3.5M | +$1.4M |
| Q3 2024 | -$2.5M | +$2.9M |
| Q2 2024 | -$4.8M | +$1.9M |
| Q1 2024 | -$4.9M | -$1.3M |
CTSO has burned cash in almost every quarter: −$9M over the past year, against −$12M the year before.
CTSO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +3.4K shares |
| 1 year | -6.5% | -218K shares |
| 3 years | +43% | +940K shares |
| 5 years | +45% | +974K shares |
| Available history | +94% | +1.5M shares |
CTSO has 3M diluted shares, down 6.5% from a year ago.
CTSO Net Leverage
CTSO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CTSO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.9 | Neutral |
| Stochastic | 31.3 | Neutral |
CTSO's weekly RSI is 40 (neutral) and its Stochastic is 31 (neutral).
CTSO PE vs Healthcare Sector
CTSO has no meaningful PE right now: it lost money over the past year.
CTSO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.54 | 18% above |
| 20 week MA | $6.09 | 12% below |
| 50 week MA | $9.78 | 45% below |
| 100 week MA | $14.6 | 63% below |
| 200 week MA | $25.4 | 79% below |
CTSO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 79% below its 200-week average.
CTSO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $76.6 | $166.2 | +117% |
| 2021 | $166.2 | $89.0 | -46% |
| 2022 | $89.0 | $28.0 | -69% |
| 2023 | $28.0 | $22.2 | -21% |
| 2024 | $22.2 | $18.8 | -15% |
| 2025 | $18.8 | $13.6 | -28% |
| 2026 YTD | $13.6 | $5.37 | -61% |
CTSO has finished five years in a row lower, and it's down 61% so far in 2026.